FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2123264723> ?p ?o ?g. }

• W2123264723 endingPage "906" @default.
• W2123264723 startingPage "896" @default.
• W2123264723 abstract "Abstract Purpose: To determine safety and feasibility of adjuvant ipilimumab following resection of high-risk melanoma and to identify surrogate markers for benefit. Experimental Design: In this phase II trial, 75 patients with resected stage IIIc/IV melanoma received the CTLA-4 antibody ipilimumab every 6 to 8 weeks for 1 year. Eligible patients received further maintenance treatments. The first 25 patients received 3 mg/kg of ipilimumab, and an additional 50 patients received 10 mg/kg. HLA-A*0201+ patients received multipeptide immunizations in combination with ipilimumab. Leukapheresis was performed prior to and 6 months after initiation of treatment. Results: Median overall and relapse-free survivals were not reached after a median follow-up of 29.5 months. Significant immune-related adverse events were observed in 28 of 75 patients and were positively associated with longer relapse-free survival. Antigen-specific T cell responses to vaccine were variable, and vaccine combination was not associated with additional benefit. No effects on T regulatory cells were observed. Higher changes in Th-17 inducible frequency were a surrogate marker of freedom from relapse (P = 0.047), and higher baseline C-reactive protein (CRP) levels were associated with freedom from relapse (P = 0.035). Conclusions: Adjuvant ipilimumab following resection of melanoma at high risk for relapse appeared to be associated with improved outcome compared to historical reports. Significant immune-related adverse events were generally reversible and appeared to be associated with improved relapse-free survival. Although vaccination failed to induce a consistent in vitro measurable response, a higher change in Th-17 inducible cells and higher baseline CRP levels were positively associated with freedom from relapse. Clin Cancer Res; 17(4); 896–906. ©2010 AACR." @default.
• W2123264723 created "2016-06-24" @default.
• W2123264723 creator A5002314862 @default.
• W2123264723 creator A5003092267 @default.
• W2123264723 creator A5003889511 @default.
• W2123264723 creator A5019378749 @default.
• W2123264723 creator A5033965725 @default.
• W2123264723 creator A5047177507 @default.
• W2123264723 creator A5052129051 @default.
• W2123264723 creator A5055519344 @default.
• W2123264723 creator A5055542783 @default.
• W2123264723 creator A5066367673 @default.
• W2123264723 creator A5082601748 @default.
• W2123264723 creator A5091759408 @default.
• W2123264723 date "2011-02-15" @default.
• W2123264723 modified "2023-10-14" @default.
• W2123264723 title "Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma" @default.
• W2123264723 cites W1536480181 @default.
• W2123264723 cites W1981528932 @default.
• W2123264723 cites W2012114706 @default.
• W2123264723 cites W2012972418 @default.
• W2123264723 cites W2041197290 @default.
• W2123264723 cites W2071483270 @default.
• W2123264723 cites W2073871857 @default.
• W2123264723 cites W2092172066 @default.
• W2123264723 cites W2093963507 @default.
• W2123264723 cites W2094366129 @default.
• W2123264723 cites W2095826876 @default.
• W2123264723 cites W2097995306 @default.
• W2123264723 cites W2105017308 @default.
• W2123264723 cites W2108768628 @default.
• W2123264723 cites W2109465910 @default.
• W2123264723 cites W2134638467 @default.
• W2123264723 cites W2140460887 @default.
• W2123264723 cites W2143467222 @default.
• W2123264723 cites W2145853100 @default.
• W2123264723 cites W2146887062 @default.
• W2123264723 cites W2148911309 @default.
• W2123264723 cites W2149244682 @default.
• W2123264723 cites W2151507811 @default.
• W2123264723 cites W2160436685 @default.
• W2123264723 cites W2162646864 @default.
• W2123264723 doi "https://doi.org/10.1158/1078-0432.ccr-10-2463" @default.
• W2123264723 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3041838" @default.
• W2123264723 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21106722" @default.
• W2123264723 hasPublicationYear "2011" @default.
• W2123264723 type Work @default.
• W2123264723 sameAs 2123264723 @default.
• W2123264723 citedByCount "176" @default.
• W2123264723 countsByYear W21232647232012 @default.
• W2123264723 countsByYear W21232647232013 @default.
• W2123264723 countsByYear W21232647232014 @default.
• W2123264723 countsByYear W21232647232015 @default.
• W2123264723 countsByYear W21232647232016 @default.
• W2123264723 countsByYear W21232647232017 @default.
• W2123264723 countsByYear W21232647232018 @default.
• W2123264723 countsByYear W21232647232019 @default.
• W2123264723 countsByYear W21232647232020 @default.
• W2123264723 countsByYear W21232647232021 @default.
• W2123264723 countsByYear W21232647232022 @default.
• W2123264723 countsByYear W21232647232023 @default.
• W2123264723 crossrefType "journal-article" @default.
• W2123264723 hasAuthorship W2123264723A5002314862 @default.
• W2123264723 hasAuthorship W2123264723A5003092267 @default.
• W2123264723 hasAuthorship W2123264723A5003889511 @default.
• W2123264723 hasAuthorship W2123264723A5019378749 @default.
• W2123264723 hasAuthorship W2123264723A5033965725 @default.
• W2123264723 hasAuthorship W2123264723A5047177507 @default.
• W2123264723 hasAuthorship W2123264723A5052129051 @default.
• W2123264723 hasAuthorship W2123264723A5055519344 @default.
• W2123264723 hasAuthorship W2123264723A5055542783 @default.
• W2123264723 hasAuthorship W2123264723A5066367673 @default.
• W2123264723 hasAuthorship W2123264723A5082601748 @default.
• W2123264723 hasAuthorship W2123264723A5091759408 @default.
• W2123264723 hasBestOaLocation W21232647231 @default.
• W2123264723 hasConcept C121608353 @default.
• W2123264723 hasConcept C126322002 @default.
• W2123264723 hasConcept C141071460 @default.
• W2123264723 hasConcept C143998085 @default.
• W2123264723 hasConcept C197934379 @default.
• W2123264723 hasConcept C203014093 @default.
• W2123264723 hasConcept C2777658100 @default.
• W2123264723 hasConcept C2777701055 @default.
• W2123264723 hasConcept C2777863537 @default.
• W2123264723 hasConcept C2781433595 @default.
• W2123264723 hasConcept C502942594 @default.
• W2123264723 hasConcept C535046627 @default.
• W2123264723 hasConcept C71924100 @default.
• W2123264723 hasConcept C8891405 @default.
• W2123264723 hasConcept C90924648 @default.
• W2123264723 hasConceptScore W2123264723C121608353 @default.
• W2123264723 hasConceptScore W2123264723C126322002 @default.
• W2123264723 hasConceptScore W2123264723C141071460 @default.
• W2123264723 hasConceptScore W2123264723C143998085 @default.
• W2123264723 hasConceptScore W2123264723C197934379 @default.
• W2123264723 hasConceptScore W2123264723C203014093 @default.
• W2123264723 hasConceptScore W2123264723C2777658100 @default.
• W2123264723 hasConceptScore W2123264723C2777701055 @default.

• next